ELAVL1 and neoplasm: Highlighting the critical role of cytoplasmic HuR in promoting tumorigenesis, small-molecule inhibitors that disrupt HuR nuclear–cytoplasmic shuttling have shown efficacy in reducing tumor growth in both in vitro and in vivo models [58].